Multiple Changes of Gene Expression and Function Reveal Genomic and Phenotypic Complexity in SLE-like Disease
The complexity of clinical manifestations commonly observed in autoimmune disorders poses a major challenge to genetic studies of such diseases. Systemic lupus erythematosus (SLE) affects humans as well as other mammals, and is characterized by the presence of antinuclear antibodies (ANA) in patient...
Saved in:
Published in | PLoS genetics Vol. 11; no. 6; p. e1005248 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
01.06.2015
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The complexity of clinical manifestations commonly observed in autoimmune disorders poses a major challenge to genetic studies of such diseases. Systemic lupus erythematosus (SLE) affects humans as well as other mammals, and is characterized by the presence of antinuclear antibodies (ANA) in patients' sera and multiple disparate clinical features. Here we present evidence that particular sub-phenotypes of canine SLE-related disease, based on homogenous (ANA(H)) and speckled ANA (ANA(S)) staining pattern, and also steroid-responsive meningitis-arteritis (SRMA) are associated with different but overlapping sets of genes. In addition to association to certain MHC alleles and haplotypes, we identified 11 genes (WFDC3, HOMER2, VRK1, PTPN3, WHAMM, BANK1, AP3B2, DAPP1, LAMTOR3, DDIT4L and PPP3CA) located on five chromosomes that contain multiple risk haplotypes correlated with gene expression and disease sub-phenotypes in an intricate manner. Intriguingly, the association of BANK1 with both human and canine SLE appears to lead to similar changes in gene expression levels in both species. Our results suggest that molecular definition may help unravel the mechanisms of different clinical features common between and specific to various autoimmune disease phenotypes in dogs and humans. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Current address: Blueprint Genetics Ltd, Helsinki, Finland Current address: Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden Conceived and designed the experiments: KLT HHH GA MW SVK GRP. Performed the experiments: MW SVK UG FHGF HDB AH. Analyzed the data: MW SVK ÖC KLT HHH. Contributed reagents/materials/analysis tools: EHS HL. Wrote the paper: SVK KLT MW HHH GA. Collected field material and performed phenotypic characterization: EHS HL. Designed the re-sequencing experiment: GRP. Performed the re-sequencing, designed the golden gate assay and performed genetic analysis: MW. Applied the multi-locus analysis: MW ÖC. Genotyped and analyzed the DLA locus: MW AH. Performed golden gate genotyping assay: UG. Performed genotyping by other methods: UG FHGF HDB. Designed the functional experiments: SVK. Analyzed the data and interpreted the association between genetic signals, gene functions and clinical signs: SVK KLT. The authors have declared that no competing interests exist. HHH and KLT share senior authorship. |
ISSN: | 1553-7404 1553-7390 1553-7404 |
DOI: | 10.1371/journal.pgen.1005248 |